BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

RevolKa Secures $1.4M in Series A Extension to Advance AI-Driven Rare Disease Drug Discovery

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein&r...

May 21, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

May 19, 2025 | News

Viva Biotech Unveils Advanced AI-Driven Drug Discovery Platform, Pioneering a New Era of Intelligent Therapeutics

Artificial intelligence has rapidly evolved from academic theory into a transformative force in pharmaceutical R&D. From early QSAR models to neur...

May 16, 2025 | News

Singapore Approves Dupixent as First Biologic Treatment for Uncontrolled COPD with Raised Eosinophils

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstru...

May 14, 2025 | News

InnoCare’s Mesutoclax Becomes First BCL2 Inhibitor to Receive Breakthrough Therapy Designation in China

-InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced&nbs...

May 13, 2025 | News

Roche and Genentech Invest $700M in First U.S. East Coast Facility to Advance Obesity Drug Manufacturing

Future 700,000 sq. ft. facility in Holly Springs, NC, will support pharma division’s metabolic medicines portfolio $700+ million investm...

May 13, 2025 | News

Taiwan’s Formosa Pharmaceuticals Partners with Apotex to Commercialize APP13007 in Mexico for Post-Ocular Surgery Treatment

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), ...

May 07, 2025 | News

China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

May 07, 2025 | Regulatory

IGI’s Trispecific Antibody ISB 2001 Receives FDA Fast Track Designation for Relapsed Multiple Myeloma

IGI, a global, fully integrated, clinical-stage biotechnology company focused on multi-species™ oncology product development, announced that th...

May 06, 2025 | News

Fangzhou Launches Otsuka’s Iclusig® Online for Leukemia Care in China

Fangzhou Inc. , a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhi...

May 06, 2025 | News

Genmab to Submit sBLA for Epcoritamab-R2 Combination in Relapsed/Refractory Follicular Lymphoma Following Positive Phase 3 Data

--Genmab A/S (Nasdaq: GMAB) announced its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to t...

May 05, 2025 | Regulatory

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

Stay Connected